[go: up one dir, main page]

WO2016188449A1 - Anticorps à domaine unique ciblant cd47 - Google Patents

Anticorps à domaine unique ciblant cd47 Download PDF

Info

Publication number
WO2016188449A1
WO2016188449A1 PCT/CN2016/083469 CN2016083469W WO2016188449A1 WO 2016188449 A1 WO2016188449 A1 WO 2016188449A1 CN 2016083469 W CN2016083469 W CN 2016083469W WO 2016188449 A1 WO2016188449 A1 WO 2016188449A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
domain antibody
nucleotide sequence
single domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2016/083469
Other languages
English (en)
Chinese (zh)
Inventor
万亚坤
孟红
卞忠华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Chunshentang Pharmaceutical Co ltd
Original Assignee
Jiangsu Chunshentang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Chunshentang Pharmaceutical Co ltd filed Critical Jiangsu Chunshentang Pharmaceutical Co ltd
Publication of WO2016188449A1 publication Critical patent/WO2016188449A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Definitions

  • the invention relates to a single domain antibody against CD47, and specifically designs a camel source single domain antibody against the extracellular segment of CD47 molecule, and belongs to the technical field of nanobodies.
  • CD47 is a membrane glycoprotein widely expressed between multiple species and tissues, which interacts with the inhibitory receptor signal-modulating protein a as a receptor and ligand, and can form a CD47-SIRPa signal complex.
  • the complex has the function of mediating two-way signal regulation and regulating a variety of immune response processes.
  • HSCs hematopoietic stem cells
  • the significance of CD47 expression is to maintain its relative stability in the body.
  • malignant diseases such as leukemia, non-Hodgkin's lymphoma, bladder cancer and breast cancer
  • Tumor cells evade tumor immunity by taking the "Don't Eat Me” signal.
  • Blocking the interaction of CD47 and SIRPa by using an anti-CD47 antibody has the effect of targeted therapy with minimal effect on normal cells.
  • targeted killing of leukemia tumor stem cells can increase the anti-tumor effect to the maximum extent, and provide a new exploration direction for the treatment of leukemia. The importance of individualization and further improvement of efficacy.
  • Nano-antibody technology is the latest and smallest antibody molecule developed by biomedical scientists based on traditional antibodies and using the molecular biology technology combined with the concept of nanoparticle science to develop the latest and smallest antibody molecules, originally by the Belgian scientist Hamers, R. It is isolated from a single heavy chain antibody in camel blood and is therefore also called a camel single-domain antibody. The single domain nature of this antibody gives it some unique properties compared to common antibodies. (1) The molecular weight is small, the structure is stable, the solubility is high, and it can be fixed in order. Nanobodies are the least known antibodies of the molecular weight and are one tenth (15 KD) of common antibodies.
  • Nanobodies Since the hydrophobic residue in the FR2 (frame-work 2) of the Nanobody is substituted with a hydrophilic residue, the water solubility of the Nanobody is increased, and the polymerizability is reduced. The study found that the Nanobody still retains 80% of the binding activity after 1 week of incubation at 37 ° C, indicating that it is easier to use and long-term storage at room temperature. Antigen binding ability can be regained after prolonged placement in an environment above 90 °C. At the same time, Nanobodies also exhibit high stability in strong denaturing agents and extreme pH environments, while ordinary antibodies undergo irreversible polymerization. Because nano-antibodies have a small volume and a regular structure, they are easier to fix and can be ordered and fixed. (2) High affinity and strong specificity.
  • Nanobodies are weakly immunogenic to humans and have good biocompatibility with humans.
  • Nano-antibodies are small in mass and simple in structure, can be encoded by a single gene, and can be expressed in large amounts in microorganisms such as yeast and E. coli by genetic engineering.
  • Nanobodies combine the advantages of traditional antibodies and small molecule drugs, and almost completely overcome the shortcomings of traditional antibody development cycle, low stability and harsh storage conditions.
  • This single-domain antibody with a molecular weight of only 1/10 of the conventional antibody has gradually become an emerging force in the diagnosis and treatment of a new generation of antibodies. Therefore, the application of nano-antibody technology to develop CD47 therapeutic antibody drugs has broad prospects.
  • the present invention provides a single domain antibody directed against the extracellular domain of CD47, and provides a coding sequence of the single domain antibody, a vector containing the coding sequence, and a host cell.
  • a single domain antibody directed against CD47 which is a single domain antibody directed against the extracellular domain of CD47, the amino acid sequence of which is represented by SEQ ID NO: 9, consisting of four framework regions and three complementarity determining regions, wherein four frameworks
  • the amino acid sequences of the regions are as shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively, and the amino acid sequences of the three complementarity determining regions are respectively SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7.
  • the complementarity determining region is mainly responsible for the recognition of antigens, and the structure of the framework region is relatively stable, mainly supporting the maintenance of protein structure.
  • nucleic acid encoding the above single domain antibody, the nucleotide sequence of which is one of the following sequences:
  • nucleotide sequence of the nucleotide sequence of (1), (2), and (3) is distinguished by the degeneracy of the genetic code.
  • the nucleotide sequence or at least a portion of the sequences of the invention can be expressed by a suitable expression system to yield the corresponding protein or polypeptide.
  • suitable expression systems include bacteria, yeasts, filamentous fungi, animal cells, insect cells, plant cells, or cell-free expression systems.
  • An expression vector comprising the above nucleic acid encoding a single domain antibody against CD47.
  • a host cell comprising the above expression vector.
  • the recipient bacteria of the host cell are preferably Escherichia coli.
  • the use of the single domain antibody against CD47 for detecting CD47 in specific application, using the ability of the single domain antibody against CD47 of the present invention to specifically bind to CD47, using an enzyme-linked immunosorbent assay (Enzyme-linked immunosorbent assay) ELISA), fluorescence immunoassay (Fluoroimmunoassay, FIA), immunochip method and affinity chromatography were performed.
  • Enzyme-linked immunosorbent assay Enzyme-linked immunosorbent assay
  • FIA fluorescence immunoassay
  • immunochip method immunochip method and affinity chromatography
  • the present invention first synthesizes a CD47 polypeptide (extracellular segment) and makes it immunogenic, and then couples the CD47 polypeptide molecule to the ELISA plate to display the correct spatial structure of the protein, and the antigen-utilizing phage display technology in this form
  • the immune nanobody gene library (the camelid heavy chain antibody phage display gene library) was screened to obtain the CD47-specific Nanobody gene, which was transferred to E. coli to establish a Nanobody capable of high expression in E. coli. Strain. Needle of the present invention
  • the single domain antibody to CD47 has broad application prospects in the development of CD47 therapeutic antibody drugs.
  • Figure 1 The insertion rate of the CD47 camel single-domain antibody library.
  • the bands from left to right are: the first is the DNA molecular marker, and the other is the PCR product of the VHH insert (single domain antibody gene fragment). It is about 500 bp in size.
  • FIG. 1 Purification map of CD47 single domain antibody, electrophoresis pattern of SDS-PAGE after purification by nickel column resin gel affinity chromatography, the results show that CD47 single domain antibody can achieve purity of more than 90% after the purification process.
  • the instruments, reagents, materials and the like involved in the following examples are conventional instruments, reagents, materials and the like which are available in the prior art unless otherwise specified, and can be obtained by a formal commercial route.
  • the experimental methods, detection methods, and the like involved in the following examples are conventional experimental methods, detection methods, and the like which have been known in the prior art unless otherwise specified.
  • the ligation product was transformed into electroporation competent cell TG1, and the CD47 Nanobody library was constructed and the storage capacity was determined.
  • the storage capacity was 5.85 ⁇ 10 8 CFU.
  • the insertion rate of the constructed library was detected, and 24 monoclonals were randomly selected. PCR analysis of the insert was performed to determine the insertion rate of the VHH fragment, and the result showed that the insertion rate of the constructed library reached 95.8% (Fig. 1).
  • the phage specifically binding to CD47 was eluted with 100 mM TEA (triethylamine), and the E. coli TG1 cells growing in log phase were infected and cultured at 37 ° C for 1 h to produce and purify the phage for the next round of screening. , The same screening process was repeated for 3 to 4 rounds, and the enrichment was gradually obtained.
  • TEA triethylamine
  • a crude antibody was obtained by an infiltration method, and the antibody was transferred to an antigen-coated ELISA plate and allowed to stand at room temperature for 1 hour.
  • mouse anti-HA tag antibody anti-mouse anti-HA antibody, purchased from Beijing Kangwei Century Biotechnology Co., Ltd.
  • the positive cloned bacteria were shaken in a LA liquid containing 100 ug/mL to extract a plasmid and perform sequencing.
  • each clone was analyzed according to the sequence alignment software Vector NTI, and the strains with the same CDR3 sequence were regarded as the same clone, and the strains with different sequences were regarded as different clones, and the amino acid sequence of the VHH chain of the antibody was SEQ ID.
  • NO: 9 is composed of 4 framework regions and 3 complementarity determining regions, wherein the amino acid sequences of the four framework regions are SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID, respectively.
  • the amino acid sequences of the three complementarity determining regions are shown in SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively.
  • the plasmids of the different clones obtained by the above sequencing analysis were electrotransformed into Escherichia coli WK6, and coated on LA+2% Gl ⁇ cose (ie containing ampicillin and glucose) culture plates, and cultured at 37 ° C overnight;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un anticorps à domaine unique ciblant la région extracellulaire de CD47, la séquence d'acides aminés de l'anticorps à domaine unique étant telle que représentée dans SEQ ID No : 9. Un acide nucléique codant pour l'anticorps, un vecteur d'expression contenant l'acide nucléique, et une cellule hôte contenant le vecteur d'expression sont en outre décrits.
PCT/CN2016/083469 2015-05-27 2016-05-26 Anticorps à domaine unique ciblant cd47 Ceased WO2016188449A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510278379.7A CN104804093A (zh) 2015-05-27 2015-05-27 一种针对cd47的单域抗体
CN2015102783797 2015-05-27

Publications (1)

Publication Number Publication Date
WO2016188449A1 true WO2016188449A1 (fr) 2016-12-01

Family

ID=53689316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/083469 Ceased WO2016188449A1 (fr) 2015-05-27 2016-05-26 Anticorps à domaine unique ciblant cd47

Country Status (2)

Country Link
CN (1) CN104804093A (fr)
WO (1) WO2016188449A1 (fr)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110003335A (zh) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒
WO2020018989A1 (fr) * 2018-07-20 2020-01-23 The Trustees Of Columbia University In The City Of New York Bactérie programmable destinée au traitement du cancer
WO2021011544A1 (fr) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Vaccins contre le vih et leurs procédés de fabrication et d'utilisation
CN112250765A (zh) * 2020-09-10 2021-01-22 哈尔滨博易诚生物科技有限公司 一种针对her2的纳米抗体及其应用
WO2021076908A1 (fr) 2019-10-18 2021-04-22 Forty Seven, Inc. Polythérapies pour le traitement de syndromes myélodysplasiques et de la leucémie myéloïde aiguë
WO2021087064A1 (fr) 2019-10-31 2021-05-06 Forty Seven, Inc. Traitement d'un cancer du sang basé sur une thérapie anti-cd47 et anti-cd20
WO2021130638A1 (fr) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Composés modulant la diacylglycérol kinase
WO2021163064A2 (fr) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
US11274123B2 (en) 2018-01-12 2022-03-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
US11311517B2 (en) 2018-11-08 2022-04-26 Aurigene Discovery Technologies Limited Combination of small molecule CD-47 inhibitors with other anti-cancer agents
WO2022190058A1 (fr) 2021-03-12 2022-09-15 Dcprime B.V. Méthodes de vaccination et utilisation d'un blocage de cd47
WO2022221304A1 (fr) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION DE LA LIAISON CD47/SIRPα ET DE LA SOUS-UNITÉ RÉGULATRICE DE L'ENZYME E1 ACTIVANT NEDD8 POUR LE TRAITEMENT DU CANCER
JP2022549362A (ja) * 2019-09-27 2022-11-24 ベイジン スターマブ バイオメド テクノロジ リミテッド 一重特異性および多重特異性抗体
WO2022271677A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
WO2022271650A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
WO2022271684A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
WO2022271659A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
JP2023516560A (ja) * 2020-02-12 2023-04-20 上海詩健生物科技有限公司 ヒトｃｄ４７を標的化するシングルドメイン抗体及びその使用
WO2023077030A1 (fr) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Composés cd73
WO2023076983A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
US11685789B2 (en) 2017-11-01 2023-06-27 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
WO2023122581A2 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023147418A1 (fr) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Inhibiteurs de parp7
EP4245756A1 (fr) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
WO2023183817A1 (fr) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop -2
WO2023196784A1 (fr) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinaisons de thérapies par anticorps pour traiter le cancer colorectal
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
CN117147830A (zh) * 2023-10-26 2023-12-01 德州国科医疗科技有限公司 一种特异性真菌d-葡聚糖检测荧光染色液
WO2024006929A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés cd73
WO2024015741A1 (fr) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
WO2024137852A1 (fr) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2024215754A1 (fr) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Composés modulateurs de kras
WO2024220917A1 (fr) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025006720A1 (fr) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Composés modulateurs de kras
WO2025024663A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
WO2025054347A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Composés de modulation de kras g12d
WO2025054530A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
US12364758B2 (en) 2020-06-30 2025-07-22 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
CN106928358B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb168
PT3402820T (pt) * 2016-01-11 2020-08-20 Forty Seven Inc Anticorpos monoclonais anti-cd47 quiméricos, de ratinho ou humanizados
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
CN109096395B (zh) * 2017-06-20 2022-06-24 华兰生物工程股份有限公司 阻断型cd47纳米抗体及其用途
CN108503708B (zh) * 2017-09-01 2021-07-30 北京智仁美博生物科技有限公司 抗人cd47抗体及其用途
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
CN110981959B (zh) * 2019-11-19 2021-05-18 深圳普瑞金生物药业有限公司 Cd47单域抗体、核苷酸序列、表达载体及试剂盒
WO2024146553A1 (fr) * 2023-01-04 2024-07-11 Wuxi Biologics (Shanghai) Co., Ltd. Anticorps dirigés contre cd47, leur procédé de préparation et leur utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133083A (zh) * 2003-11-11 2008-02-27 中外制药株式会社 人源化的抗cd47抗体
WO2014093678A2 (fr) * 2012-12-12 2014-06-19 Frazier William A Anticorps anti-cd47 thérapeutiques
CN104271757A (zh) * 2012-02-06 2015-01-07 印希彼有限责任公司 Cd47抗体及其使用方法
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333248B (zh) * 2013-06-07 2014-07-09 东南大学 一种cd25纳米抗体、其编码序列及应用
CN103421115B (zh) * 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133083A (zh) * 2003-11-11 2008-02-27 中外制药株式会社 人源化的抗cd47抗体
CN104271757A (zh) * 2012-02-06 2015-01-07 印希彼有限责任公司 Cd47抗体及其使用方法
WO2014093678A2 (fr) * 2012-12-12 2014-06-19 Frazier William A Anticorps anti-cd47 thérapeutiques
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11685789B2 (en) 2017-11-01 2023-06-27 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules
US11560403B2 (en) 2018-01-12 2023-01-24 Aurigene Oncology Limited 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways
US11274123B2 (en) 2018-01-12 2022-03-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling
WO2020018989A1 (fr) * 2018-07-20 2020-01-23 The Trustees Of Columbia University In The City Of New York Bactérie programmable destinée au traitement du cancer
US12350297B2 (en) 2018-07-20 2025-07-08 The Trustees Of Columbia University In The City Of New York Programmable bacteria for the treatment of cancer
US12268670B2 (en) 2018-11-08 2025-04-08 Aurigene Oncology Limited Combination of small molecule CD-47 inhibitors with other anti-cancer agents
US11311517B2 (en) 2018-11-08 2022-04-26 Aurigene Discovery Technologies Limited Combination of small molecule CD-47 inhibitors with other anti-cancer agents
CN110003335A (zh) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒
WO2021011544A1 (fr) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Vaccins contre le vih et leurs procédés de fabrication et d'utilisation
EP4034549A4 (fr) * 2019-09-27 2024-03-06 Beijing Starmab Biomed Technology Ltd Anticorps monospécifiques et multispécifiques
JP2022549362A (ja) * 2019-09-27 2022-11-24 ベイジン スターマブ バイオメド テクノロジ リミテッド 一重特異性および多重特異性抗体
WO2021076908A1 (fr) 2019-10-18 2021-04-22 Forty Seven, Inc. Polythérapies pour le traitement de syndromes myélodysplasiques et de la leucémie myéloïde aiguë
EP4349413A2 (fr) 2019-10-18 2024-04-10 Forty Seven, Inc. Polythérapies pour le traitement de syndromes myélodysplasiques et de leucémie myéloïde aiguë
WO2021087064A1 (fr) 2019-10-31 2021-05-06 Forty Seven, Inc. Traitement d'un cancer du sang basé sur une thérapie anti-cd47 et anti-cd20
WO2021130638A1 (fr) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Composés modulant la diacylglycérol kinase
EP4445902A2 (fr) 2019-12-24 2024-10-16 Carna Biosciences, Inc. Composés modulant la diacylglycérol kinase
JP2023516560A (ja) * 2020-02-12 2023-04-20 上海詩健生物科技有限公司 ヒトｃｄ４７を標的化するシングルドメイン抗体及びその使用
JP7473248B2 (ja) 2020-02-12 2024-04-23 上海詩健生物科技有限公司 ヒトｃｄ４７を標的化するシングルドメイン抗体及びその使用
US12297282B2 (en) 2020-02-14 2025-05-13 Gilead Sciences, Inc. Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)
WO2021163064A2 (fr) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US12364758B2 (en) 2020-06-30 2025-07-22 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN112250765A (zh) * 2020-09-10 2021-01-22 哈尔滨博易诚生物科技有限公司 一种针对her2的纳米抗体及其应用
WO2022190058A1 (fr) 2021-03-12 2022-09-15 Dcprime B.V. Méthodes de vaccination et utilisation d'un blocage de cd47
WO2022221304A1 (fr) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION DE LA LIAISON CD47/SIRPα ET DE LA SOUS-UNITÉ RÉGULATRICE DE L'ENZYME E1 ACTIVANT NEDD8 POUR LE TRAITEMENT DU CANCER
WO2022271650A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
WO2022271677A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
WO2022271659A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
WO2022271684A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
WO2023076983A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Dérivés de pyridine-3(2h)-one
WO2023077030A1 (fr) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Composés cd73
EP4667056A1 (fr) 2021-12-22 2025-12-24 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
WO2023122581A2 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
WO2023147418A1 (fr) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Inhibiteurs de parp7
WO2023178181A1 (fr) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
EP4245756A1 (fr) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
EP4464703A2 (fr) 2022-03-17 2024-11-20 Gilead Sciences, Inc. Agents de dégradation de la famille des doigts de zinc de l'ikaros et leurs utilisations
WO2023183817A1 (fr) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop -2
WO2023196784A1 (fr) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinaisons de thérapies par anticorps pour traiter le cancer colorectal
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2024006929A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Composés cd73
WO2024015741A1 (fr) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Polypeptides immunogènes du vih et vaccins et utilisations de ceux-ci
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
WO2024137852A1 (fr) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2024215754A1 (fr) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Composés modulateurs de kras
WO2024220917A1 (fr) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025006720A1 (fr) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Composés modulateurs de kras
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
WO2025024663A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
WO2025054530A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d
WO2025054347A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Composés de modulation de kras g12d
CN117147830B (zh) * 2023-10-26 2024-01-12 德州国科医疗科技有限公司 一种特异性真菌d-葡聚糖检测荧光染色液
CN117147830A (zh) * 2023-10-26 2023-12-01 德州国科医疗科技有限公司 一种特异性真菌d-葡聚糖检测荧光染色液
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations

Also Published As

Publication number Publication date
CN104804093A (zh) 2015-07-29

Similar Documents

Publication Publication Date Title
WO2016188449A1 (fr) Anticorps à domaine unique ciblant cd47
CN110003335A (zh) Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒
CN110872353B (zh) 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用
CN106928363B (zh) 一种FAP纳米抗体Nb12
CN110862457B (zh) 能与碳酸酐酶ix特异性结合的骆驼源纳米抗体及其应用
CN117986360B (zh) Il18蛋白的特异性抗体及其制备方法与应用
KR20200003235A (ko) arm-PCR 및 고속 처리 서열 분석을 이용한 항원 특이적 후천성 면역 반응의 확인
CN112250765A (zh) 一种针对her2的纳米抗体及其应用
CN112812180A (zh) 一种bax纳米抗体库及其制备方法与应用
CN106928364A (zh) 一种FAP纳米抗体Nb26
CN107759692A (zh) 一种抗ca125的纳米抗体
CN106928358B (zh) 一种CD105纳米抗体Nb168
CN106928365B (zh) 一种FAP纳米抗体Nb36
CN110129277B (zh) 一种肝癌诊断标志物brix1及其应用
CN106957367B (zh) 抗idh1 r132h抗体及其制备方法和用途
CN112239504A (zh) 一种针对pd-l1的纳米抗体及其应用
CN106928360B (zh) 一种CD105纳米抗体Nb68
CN115960238A (zh) 一种能特异性结合pcsk9抗原的纳米抗体及其制备方法
CN106928368B (zh) 一种FAP纳米抗体Nb57
CN112210009A (zh) 一种针对pd1的单域抗体及其应用
CN116082509B (zh) 一种单域抗体及其制备方法和应用
CN114805578A (zh) 一种白细胞免疫球蛋白样受体亚家族b成员2的羊驼纳米抗体、制备方法及其应用
CN119371532B (zh) 抗cd99蛋白的单域抗体及其编码基因和应用
CN111978382B (zh) 一种球形孢子丝菌Gp70重组蛋白的制备方法及其应用
CN116496392B (zh) 抗新型冠状病毒n蛋白单域抗体、融合蛋白及其编码基因和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16799336

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03.04.2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16799336

Country of ref document: EP

Kind code of ref document: A1